China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly Current Deferred Revenue came in at $61746.0 in Q1 2026, down 46.04% YoY from $114435.0 in Q1 2025, and down 44.66% on a QoQ basis from $111580.0 in Q4 2025.
China Pharma Holdings (CPHI) Current Deferred Revenue (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has 17 years of Current Deferred Revenue data on file, last reported at $61746.0 in Q1 2026.
- Quarterly Current Deferred Revenue fell 46.04% year-over-year to $61746.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $61746.0 (down 46.04% YoY) and the FY2025 annual result came in at $111580.0, down 31.21% from the prior year.
- Current Deferred Revenue declined to $61746.0 in Q1 2026, from $111580.0 in the prior quarter.
- In the past five years, Current Deferred Revenue ranged from a high of $520295.0 in Q4 2022 to a low of $24920.0 in Q3 2024.
- A 5-year average of $130953.5 and a median of $112357.0 in 2024 frame the typical range for Current Deferred Revenue.
- Annual changes were most pronounced in 2024 — Current Deferred Revenue tumbled 85.52% — and 2025, when it soared 385.2%.
- Tracing CPHI's Current Deferred Revenue over 5 years: stood at $520295.0 in 2022, then sank by 82.6% to $90507.0 in 2023, then surged by 79.22% to $162208.0 in 2024, then slumped by 31.21% to $111580.0 in 2025, then plunged by 44.66% to $61746.0 in 2026.
- The last three Current Deferred Revenue figures came in at $61746.0 (Q1 2026), $111580.0 (Q4 2025), and $120912.0 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Haleon | 43.85 Bn | 42.88 Bn | - |
| 2 | Teva Pharmaceutical Industries | 43.02 Bn | 39.37 Bn | 2.15 Bn |
| 3 | Zoetis | 31.47 Bn | 29.79 Bn | 1.05 Bn |
| 4 | Takeda Pharmaceutical | 28.59 Bn | 22.79 Bn | 5.10 Bn |
| 5 | United Therapeutics | 22.20 Bn | 19.53 Bn | 683.80 Mn |
| 6 | Viatris | 18.76 Bn | 17.87 Bn | 1.46 Bn |
| 7 | Neurocrine Biosciences | 15.45 Bn | 15.06 Bn | 935.80 Mn |
| 8 | Elanco Animal Health | 11.76 Bn | 11.23 Bn | 798.00 Mn |
| 9 | Dr Reddys Laboratories | 10.10 Bn | 9.94 Bn | - |
| 10 | China Pharma Holdings | 42.14 Mn | 41.84 Mn | 83,566.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 61,746.00 |
| Dec 31, 2025 | 111,580.00 |
| Sep 30, 2025 | 120,912.00 |
| Jun 30, 2025 | 77,683.00 |
| Mar 31, 2025 | 114,435.00 |
| Dec 31, 2024 | 162,208.00 |
| Sep 30, 2024 | 24,920.00 |
| Jun 30, 2024 | 101,056.00 |
| Mar 31, 2024 | 112,357.00 |
| Dec 31, 2023 | 90,507.00 |
| Sep 30, 2023 | 172,110.00 |
| Jun 30, 2023 | 61,334.00 |
| Mar 31, 2023 | 136,681.00 |
| Dec 31, 2022 | 520,295.00 |
| Sep 30, 2022 | 84,048.00 |
| Jun 30, 2022 | 138,238.00 |
| Mar 31, 2022 | 136,099.00 |
| Dec 31, 2021 | 210,028.00 |
| Sep 30, 2021 | 420,039.00 |
| Jun 30, 2021 | 525,579.00 |